CTAP 201

Drug Profile

CTAP 201

Alternative Names: CTAP201 Injection

Latest Information Update: 11 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytochroma
  • Developer OPKO Health
  • Class Vitamins
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Secondary hyperparathyroidism

Most Recent Events

  • 04 Mar 2013 Cytochroma has been acquired by OPKO Health
  • 10 May 2010 Safety and efficacy data from a phase I study in Secondary hyperparathyroidism were released by Cytochroma
  • 06 Jan 2009 Phase-I clinical trials in Secondary hyperparathyroidism in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top